For the first time, WHO’s treatment guidelines consist of a clear suggestion for the usage of prolonged-performing injectable cabotegravir and rilpivirine (CAB/RPV) instead switching selection for antiretroviral therapy (ART) for Older people and adolescents that have reached entire viral suppression on oral ART and don't have active hepatitis B an https://goo.gl/maps/UueY6cwcpDNXRohh7